The Responsible Development of Adeno-Associated Virus Gene Therapies
Human Gene Therapy · 2025
DOI: 10.1177/10430342251359668 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, 2025. Verfasst von James M Wilson und 1 weiteren Autor:innen. Beteiligte Einrichtung: GEMMA Biotherapeutics Inc., Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Several unexpected fatalities in patients who received adeno-associated virus (AAV)-based gene therapies have recently occurred. These tragic events have cast a pall over the entire sector with some stakeholders suggesting that AAV is patently unsafe as a gene delivery platform and ought not to be pursued. This conclusion is not warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- GEMMA Biotherapeutics Inc., Philadelphia, Pennsylvania, USA.
- NYU Grossman School of Medicine, New York, New York, USA.
Zitieren
APA
Wilson, J. M., & Caplan, A. L. (2025). The Responsible Development of Adeno-Associated Virus Gene Therapies. Human Gene Therapy. https://doi.org/10.1177/10430342251359668
Vancouver
Wilson JM, Caplan AL. The Responsible Development of Adeno-Associated Virus Gene Therapies. Human Gene Therapy. 2025. doi:10.1177/10430342251359668
BibTeX
@article{Wilson2025,
author = {Wilson, James M and Caplan, Arthur L},
title = {The Responsible Development of Adeno-Associated Virus Gene Therapies},
journal = {Human Gene Therapy},
year = {2025},
doi = {10.1177/10430342251359668}
}
EUVIMED